Back to Search

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

  • Protocol Number: 201807049
  • Principal Investigator: Govindan, Ramaswamy
  • Cancer Types: Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC

Protocol Interventions

Tarlatamab, Pembrolizumab, CRS Mitigation Strategies